

Index

- abdomino-pelvic irradiation
 effects on fertility, 321–322
 fertility preservation, 328
 pregnancy outcomes after, 327
- ABO incompatibility, fetal, 126
- ABVD chemotherapy regimen,
 311–312, 325, 328
- acidosis, massive transfusion, 212
- activated partial thromboplastin time
 (aPTT), 11, 170
 obstetric hemorrhage, 217, 223
 pre-eclampsia, 275
- activated protein C (APC)
 resistance assay, 10, 132, 194
 trophoblast development, 191
- active management of third stage of
 labor, 199, 316
- acute chest syndrome (ACS),
 58, 62
- acute fatty liver of pregnancy (AFLP),
 287–288
 differential diagnosis, 278, 283, 287
 pathogenesis, 287–288
- acute hematological malignancies,
 309–316. *See also* leukemia;
 lymphoma
 case study, 317
 peripartum management, 316
 sepsis in pregnancy, 315
 supportive therapies in pregnancy,
 315–316
- acute lymphoblastic leukemia (ALL)
 case study, 330
 incidence in pregnancy, 313
 late effects on fertility, 324
 management in pregnancy, 314
- acute myeloid leukemia (AML)
 case study, 317
 incidence in pregnancy, 313
 late effects on fertility, 324
 management in pregnancy, 313–314,
 328
 peripartum management, 316
 septic complications, 315
- ADAMTS 13
 congenital deficiency, 283, 285
 HELLP syndrome, 285
 inhibitors/IgG antibodies, 285
 monitoring during pregnancy, 286
 normal pregnancy, 284–285
- TTP pathophysiology, 284
- age-related risk, VTE, 140
- alpha fetoprotein (AFP), 283
- α 2-antiplasmin, 9
- α 2-macroglobulin, 9
- α -thalassemias, 66, 67, 78
 antenatal screening, 80
 case study, 91
 deletion mutations (α^0 thalassemia),
 85, 87
 global distribution, 66, 79
 prenatal diagnosis, 79, 85, 87
 risk of affected offspring, 69
- altitude, Hb concentrations at, 1
- amniocentesis
 hemoglobinopathies, 85, 87
 hemophilia, 261–262
 RhD isoimmunization, 117–118, 120
- amniotic fluid embolism (AFE)
 hemostatic impairment, 211, 217
 salvaged blood, 213
- amphotericin B, 315
- anagrelide, 302, 303, 304–305
- analgesia
 labor. *See* labor analgesia
 painful sickle crises, 62
- anemia
 definition, 1
 exchange transfusion, 123–124
 fetal. *See* fetal anemia
 hereditary spherocytosis, 94
 iron deficiency. *See* iron deficiency
 myelodysplastic syndrome, 314–315
 physiological/dilutional, of
 pregnancy, 15
 thalassemia, 66, 70
 transfusion dependent, 94
 vitamin B₁₂ deficiency, 30
- anesthesia. *See also* general anesthesia;
 labor analgesia; regional
 anesthesia
 fully anticoagulated women,
 171–172
 obstetric hemorrhage, 210
 women on thromboprophylaxis,
 167–169
- anesthetists
 antenatal assessment, 206
 management of obstetric
 hemorrhage, 206–214
- angiotensin receptor II blockers,
 60, 272
- angiotensin-converting enzyme (ACE)
 inhibitors, 60, 272
- antepartum hemorrhage (APH), 197,
See also obstetric hemorrhage
 anesthetic management, 206–214
- anticoagulated women, 170
 case study, 12–13
 diagnosis, 200
 obstetric management, 200
- anthracyclines, 313
- anti-A antibodies, 126
- anti-B antibodies, 126
- anti-beta 2 glycoprotein 1 (anti- β 2-GP
 I) antibodies, 178
 assay, 181
 procoagulant effects, 178–179
- antibiotics, 160, 315
- anti-c antibodies, 125
- anticardiolipin antibodies (aCL), 178,
 181
- anti-CD20 monoclonal antibodies,
 325–326. *See also* rituximab
- anticoagulants. *See also* heparin;
 warfarin
 newer, 173
 oral. *See* vitamin K antagonists
 physiological, 10–11
- anticoagulation (therapeutic), 165–174,
See also thromboprophylaxis
 acute VTE in pregnancy, 132–133
 anesthetic considerations, 171–172
 antiphospholipid syndrome,
 183, 185
 breast-feeding safety, 134
 case studies, 136–137, 174, 186
 maintenance antenatal, 133
 massive pulmonary embolism, 136
 myeloproliferative neoplasms, 302
 near patient testing, 173–174
 peripartum management, 133–134,
 165–174
 postpartum continuation, 134
 prosthetic heart valves, 145,
 150–160
 rapid reversal, 158–159, 171
- anti-D antibodies
 antenatal testing, 119–120
 assay methods, 117

Index

- anti-D immunoglobulin prophylaxis, 114–116
 first trimester, 115
 hematological malignancies, 316
 improving safety, 126
 ITP, 47
 postpartum, 115
 recombinant monoclonal antibodies, 126
 refusal, 116
 routine antenatal (RAADP), 115–116
- anti-E antibodies, 125
- anti-embolism stockings (AES). *See* graduated elastic compression stockings
- antiemetics, 315
- antifungal agents, 315
- antihypertensive agents, 271–272, 274
- anti-Kell antibodies, 125, 127
- anti-La antibodies, 182–183
- anti-mullerian hormone (AMH), 320–321
- antiphospholipid antibodies (aPL), 48, 178–179
 case study, 186
 isolated, without prior problems, 185
 laboratory evaluation, 181–182
 pathophysiological mechanisms, 178–179
- antiphospholipid syndrome (APS), 177–186
 case studies, 186
 catastrophic (CAPS), 181
 classification criteria, 177
 clinical features, 179–181, 283
 epidemiology, 178
 laboratory evaluation, 181–182
 management, 182–186
 neonatal, 186
 pathophysiology and etiology, 178–179
 pre-eclampsia, 180, 271
 primary (PAPS), 177
 secondary (SAPS), 177
 seronegative (SNAPS), 185
 thromboprophylaxis, 142, 144
- antiplatelet agents. *See also* aspirin
 peripartum period, 166
 pre-eclampsia, 272–273
 prosthetic heart valves, 156, 157
- anti-Ro antibodies, 182–183, 186
- antithrombin, 9–11
 concentrates, pre-eclampsia, 273
 testing in pregnancy, 132, 194
- antithrombin deficiency, 189–190
 pregnancy loss, 191
 thromboprophylaxis, 132, 142, 144
- antithrombotic therapy
 inherited thrombophilia, 192–193
 myeloproliferative neoplasms, 303–304
 pre-eclampsia, 272–273
- anti-Xa monitoring
 antenatal, 133, 142
 peripartum period, 170
 prosthetic heart valves, 156–157
- apixaban, 134, 145, 151, 173
- aplastic anemia, 99
- argatroban, 173
- ARMS (amplification refractory mutation system), 85–86
- arterial thrombosis
 antiphospholipid syndrome, 179
 previous, 183
- ascites, fetal, 113
- L-asparaginase, 314
- aspirin
 antenatal thromboprophylaxis, 144
 antiphospholipid syndrome, 182, 184
 inherited thrombophilia, 193, 195
 myeloproliferative neoplasms, 297, 300–301, 303, 304
 peripartum period, 166
 pre-eclampsia, 272–273
 prosthetic heart valves, 152, 156, 157
 sickle cell disease, 61
 thalassemia, 70
- assisted reproductive techniques. *See also* preimplantation genetic diagnosis
 antiphospholipid syndrome, 185, 186
 cancer patients, 328–330
- asthma, 270
- autism spectrum disorder, 270
- autoimmune cytopenias, 40–54
- autoimmune hemolytic anemia (AIHA), 40, 51–54
- autoimmune neutropenia (AIN), 40, 49–51
- azathioprine, 47, 185
- balloon tamponade, uterus, 202
- Barker hypothesis, 270
- basophil count, 3, 4
- bendamustine, 326
- Bernard–Soulier syndrome (BSS), 44, 242–243
- beta 2 glycoprotein 1 antibodies. *See* anti-beta 2 glycoprotein 1 antibodies
- beta-human chorionic gonadotrophin (hCG), 283
- β -thalassemias
 antenatal screening, 80
 case studies, 74–75
 global distribution, 66
 prenatal diagnosis, 78, 84, 85, 86
 risk of affected offspring, 69
- betrixaban, 173
- bilirubin
 amniotic fluid, 117, 118
 hemolytic disease of fetus and newborn, 112, 113
- bisphosphonates, 72
- bleeding disorders, heritable. *See* inherited bleeding disorders
- bleeding/hemorrhage
 intracranial. *See* intracranial hemorrhage
 maternal von Willebrand disease, 237
 neonatal hemophilia, 247, 248–249
 neonatal thrombocytopenia, 49, 105
 neonatal von Willebrand disease, 239
 obstetric. *See* obstetric hemorrhage
- blood films
 iron deficiency anemia, 20
 ITP, 44
 vitamin B₁₂ deficiency, 33
- blood loss estimation, obstetric hemorrhage, 209, 210
- blood transfusion
 autoimmune hemolytic anemia, 53
 complications of massive, 211–212
 fetal, hemolytic disease, 118–119, 122
 fixed ratio protocols, severe PPH, 211, 222, 223
 hematological malignancies, 316
 iron deficiency anemia, 23, 25
 neonatal exchange transfusion, 123–124
 obstetric hemorrhage, 210–211, 220–223
 sickle cell disease, 61–62
 thalassemia, 67–68, 70
- blood volume, 1, 15
- B-Lynch brace suture, 203
- bone disease, thalassemia, 72
- bone marrow examination
 autoimmune neutropenia, 50–51
 folate deficiency, 36
 idiopathic thrombocytopenic purpura, 44
 iron deficiency, 20–21
 vitamin B₁₂ deficiency, 33, 34
- bone marrow failure syndromes, inherited, 99
- breast-feeding
 anticoagulated women, 134, 160, 167
 myeloproliferative neoplasms, 304–305
- Burkitt lymphoma, 310, 312–313
- busulfan, 322–324
- C4b-binding protein, 10
- calreticulin (*CALR*) gene mutations, 297
- carbetocin, 202

- carboprost, 201, 210
 cardiac disease
 pre-eclampsia and, 269–270
 thalassemia, 68–69, 71–72
 cardiopulmonary bypass, 173
 caspofungin, 315
 cauda equina syndrome, anticoagulated women, 172
 cell salvage, obstetric hemorrhage, 212–214
 central neuraxial blockade (CNB), 165,
 See also epidural analgesia;
 regional anesthesia
 fully anticoagulated women, 172
 von Willebrand disease, 239–240
 women on thromboprophylaxis,
 167–169
 cesarean section (CS)
 cell salvage, 212–214
 fully anticoagulated women, 134,
 171–172
 hematological malignancies, 316
 hemorrhage during, case studies,
 214–215
 ITP, 48
 sickle cell disease, 59
 women on thromboprophylaxis, 168
 chelation therapy
 sickle cell disease, 60
 thalassemia, 67, 70, 71
 transfusion dependent anemias, 94
 chemoradiotherapy, 320–330, *See also*
 chemotherapy; radiotherapy
 chemotherapy
 acute leukemias, 313–314, 324
 agents, classification, 323
 effects during pregnancy, 327–328
 fertility after, 322–327
 fertility preservation, 328–330
 Hodgkin's disease, 311–312, 325
 non-Hodgkin's lymphoma, 312–313,
 325, 326
 pregnancy outcomes after, 327
 supportive therapies, 315–316
 timing of delivery, 316
 chest X-ray (CXR), 130–131
 chlorambucil, 324
 cholelithiasis, thalassemia, 72
 chondrodysplasia punctata,
 152, 154
 CHOP chemotherapy regimen, 312,
 326
 chorea gravidarum, 185
 chorionic villus sampling (CVS)
 hemoglobinopathies, 85, 87
 hemophilia, 261
 chronic idiopathic neutropenia (CIN),
 50
 chronic myeloid leukemia (CML),
 324–325, 327
 CLASP (Collaborative Low-dose
 Aspirin Study in Pregnancy), 272
 clopidogrel, 166
 coagulation factors
 during PPH, 217, 218
 normal pregnancy, 8, 10, 251
 rare deficiencies, 251–252, 255
 coagulation tests
 obstetric hemorrhage, 12–13,
 219–220
 point of care, 11–13
 routine, 11
 coagulopathies
 inherited, 246–252
 obstetric hemorrhage, 212, 217–219
 cold hemagglutinin disease (CHAD),
 52, 53
 colloids, obstetric hemorrhage, 208
 combined spinal epidural (CSE), 168
 complement activation, hemolytic
 uremic syndrome, 289
 compression stockings. *See* graduated
 elastic compression stockings
 computed tomography pulmonary
 angiography (CTPA), 130, 131
 congenital dyserythropoietic anemia
 (CDA), 97–98, 100
 congenital heart disease, 150, 160
 consent, cryopreservation of gametes,
 329–330
 contraception
 sickle cell disease, 59–60
 thalassemia, 70–71
 controlled cord traction, 199
 Coombs test, 117
 corticosteroids
 acute TTP, 286
 antiphospholipid syndrome, 182, 184
 autoimmune hemolytic anemia, 53
 complications of maternal, 108
 FNAIT, 107, 108
 HELLP syndrome, 277
 hematological malignancies, 316
 ITP, 45–47, 54
 myelosuppressed women, 315
 systemic lupus erythematosus, 185
 cranial irradiation, 321
 critical care, obstetric hemorrhage, 214
 cryoprecipitate, obstetric hemorrhage,
 221, 222
 crystalloids, obstetric hemorrhage, 208
 cyanocobalamin, oral, 35
 cyclophosphamide, ovarian toxicity,
 322–324
 cytarabine (cytosine arabinoside),
 313–314
 cytopenias, autoimmune, 40–54
 cytoreductive therapy,
 myeloproliferative neoplasms,
 302, 303, 304–305
 dabigatran, 134, 145, 151, 173
 dalteparin
 acute VTE in pregnancy, 133
 inherited thrombophilia, 193
 myeloproliferative neoplasms, 302
 prosthetic heart valves, 157
 thromboprophylaxis, 145
 danaparoid, 145
 daunorubicin, 313
 D-dimers, 9
 sickle cell disease, 63
 suspected VTE, 131–132
 deep venous thrombosis (DVT), 129,
 See also venous thromboembolism
 antiphospholipid syndrome, 179
 case studies, 136–137
 diagnosis, 130
 management in pregnancy, 132–133
 sites in pregnancy, 129–130
 symptoms and signs, 129, 130
 deferasirox, 71, 94
 deferiprone, 71, 94
 deferoxamine (desferrioxamine), 60,
 71, 74, 94
 delivery, care during. *See* peripartum
 management
 desmopressin (DDAVP)
 hemophilia, 247, 248
 von Willebrand disease, 238, 239
 dexamethasone, 277, 316
 diabetes mellitus
 gestational, 24
 thalassemia, 72
 Diamond-Blackfan anemia (DBA),
 98–99
 dietary advice, iron intake, 21
 diffuse large B cell lymphoma (DLBCL),
 309–310, 312–313
 digital PCR, 89
 dinoprostone, 202
 disseminated intravascular coagulation
 (DIC), 290
 placental abruption, 277
 postpartum hemorrhage, 218
 pre-eclampsia, 275
 thrombocytopenia, 42
 DNA analysis. *See* genetic testing
 drug-induced thrombocytopenia, 42
 dysfibrinogenemia, 251–252
 dyskeratosis congenita, 99
 echinocytes, 96
 eclampsia, management, 274–275
 ecluzimab, 289
 edoxaban, 134, 151
 electrolyte imbalance, massive
 transfusion, 212
 electrophoresis, hemoglobin, 80
 elliptocytosis, hereditary, 95
 eltrombopag, ITP, 47

Index

- embolization, systemic, 151
 embryo cryopreservation, 328–329
 embryo loss, maternal thrombophilia, 192
 endoglin (Eng), 268, 271
 endothelial dysfunction, pre-eclampsia, 268
 enoxaparin
 acute VTE in pregnancy, 133
 inherited thrombophilia, 193
 myeloproliferative neoplasms, 302
 prosthetic heart valves, 156, 157
 thromboprophylaxis, 145
 eosinophil count, 3, 4
 epidural analgesia. *See also* central neuraxial blockade
 anticoagulated women, 168–169
 antiphospholipid syndrome, 185
 ITP, 47–48, 54
 epidural blood patch, anticoagulated women, 172
 ergometrine, 201, 209
 erythroblastosis fetalis, 112, 123
 erythrocytes. *See* red cells
 erythrocytosis, 97, 299–300
 erythroferrone, 18
 erythropoiesis, 93–94
 erythropoietin, 23, 93–94
 essential thrombocythemia (ET), 293–305
 case studies, 305, 306
 diagnosis, 299
 management, 303–305
 pathogenesis, 297–299
 pregnancy outcomes, 293, 294
 treatment options, 300–303
 ethical issues, cryopreservation of gametes, 329–330
 ethnic differences
 Hb concentrations, 1, 15
 neutrophil counts, 50
 RhD status, 113, 124
 evacuation of retained products of conception (ERPC), 202
 examination under anesthesia (EUA), postpartum hemorrhage, 202
 exchange transfusion, 123–124

F8 gene mutations, 258, 259
F9 gene mutations, 258
 factor II deficiency, 251–252
 factor V deficiency, 251–252
 factor V Leiden (FVL), 190
 case study, 195
 diagnosis in pregnancy, 132, 194
 pre-eclampsia, 271
 pregnancy loss, 191
 VTE risk, 132, 144
 factor VII deficiency, 251–252
 factor VIIa, recombinant (rFVIIa)
 factor VII deficiency, 251
 factor XI deficiency, 250
 Glanzmann's thrombasthenia, 242
 obstetric hemorrhage, 211, 223
 factor VIII (FVIII)
 activity in hemophilia carriers, 257–258
 deficiency. *See* hemophilia
 management, hemophilia, 247–248
 normal pregnancy, 7, 237, 246, 284–285
 VWF concentrates, 238–239
 VWF interaction, 234
 factor VIII: von Willebrand factor (FVIII:VWF) ratio, 257–258
 factor IX
 activity in hemophilia carriers, 257–258
 deficiency. *See* hemophilia
 management, hemophilia, 247–248
 normal pregnancy, 246
 factor X deficiency, 251–252
 factor XI
 concentrate, 250
 deficiency, 249–251
 factor XIII
 deficiency, 251–252
 normal pregnancy, 9
 Fanconi's anemia, 42, 99
 fentanyl, 171
 ferritin
 iron storage, 16
 serum, 2, 19, 20
 ferroportin, 17, 18
 fertility/infertility
 acute leukemias, 324
 chronic myeloid leukemia, 324–325
 effects of chemotherapy, 322–324
 effects of radiotherapy, 321–322
 lymphomas, 325–326
 mechanisms of chemoradiotherapy effects, 320–321
 preservation, 328–330
 sickle cell disease, 59–60
 thalassemia, 70–71
 fetal anemia
 clinical features, 112, 113
 diagnosis of immune-mediated, 117–118
 intrauterine treatment, 118–119
 middle cerebral artery flow, 120–122
 pathogenesis, 112
 fetal blood sampling (FBS)
 FNAIT, 106–109
 hemoglobinopathies, 85
 RhD isoimmunization, 117
 fetal growth restriction. *See* intrauterine growth restriction
 fetal sexing, hemophilia, 260–261
 fetal/neonatal alloimmune thrombocytopenia (FNAIT), 103–109
 antenatal management, 106–109, 110
 antenatal screening, 105
 case reports, 110–111
 clinical significance, 104, 105
 diagnosis, 104
 differential diagnosis, 48, 103
 epidemiology, 103–104
 information for mother, 106
 inherited disorders of platelet function, 242
 postnatal management, 49, 105–106, 110–111
 subsequent pregnancies, 104–105
 fetomaternal hemorrhage (FMH), 112
 causes, 112, 115
 determination of size, 115
 fibrin clot, 8
 fibrinogen, 8–9
 as biomarker of PPH progression, 218–219, 220
 as transfusion trigger, 211
 during PPH, 217, 221–222
 inherited disorders, 251–252
 laboratory evaluation, 11, 219–220
 pre-eclampsia, 275
 fibrinogen concentrate
 dysfibrinogenemia, 252
 obstetric hemorrhage, 211, 221–222
 fibrinolysis, 9
 FIBTEM®, 11–13
 fluconazole, 315
 fluid resuscitation, obstetric hemorrhage, 202, 208–209
 Fms-like tyrosine kinase, soluble (sFlt-1), 268, 271
 FNAIT. *See* fetal/neonatal alloimmune thrombocytopenia
 folate
 erythrocyte, 2, 36
 food fortification, 37
 metabolism, 29, 35
 plasma, 2, 36
 folate deficiency, 35–38
 case study, 37
 causes, 35–36
 management, 35, 36–38
 folic acid supplements
 autoimmune hemolytic anemia, 53
 bioavailability, 35
 folate deficiency, 37–38
 inherited red cell disorders, 94
 peri-conceptual, 36–37
 pyruvate kinase deficiency, 96–97
 sickle cell disease, 60
 thalassemia, 70, 71
 vitamin B₁₂ deficiency, 35
 follicular lymphoma, 309, 312–313

- fondaparinux
 peripartum therapy, 169, 173, 174
 thromboprophylaxis, 145
- food fortification, folate, 37
- free fetal DNA (ffDNA), maternal plasma
 fetal sexing in hemophilia carriers, 261
- hemoglobinopathies, 88–89
- hemophilia mutation
 detection, 262
 RhD status, 120
- fresh frozen plasma (FFP)
 anticoagulant reversal, 158
 factor XI deficiency, 250
 obstetric hemorrhage, 211, 217, 222–223
 rare coagulation factor deficiencies, 251
- full blood count, normal pregnancy, 11
- Gap-PCR, 86, 87
- gemprost, 202
- general anesthesia
 anticoagulated women, 171–172
 obstetric hemorrhage, 210
- genetic counseling, 255–260
 case studies, 263
 hemophilia, 255–260
 rare bleeding disorders, 262
- genetic testing
 excluding maternal contamination, 87, 88
 female hemophilia carriers, 258–260
 fetal sex determination, 261
 hemoglobinopathies, 85–87
 polycythemia vera, 299
 RhD status, 116–117, 120
- genital tract trauma, 210–211, 217, 218
- gestational diabetes, 24
- gestational hypertension, 266
- gestational thrombocytopenia, 4, 7–8, 282–283
 case study, 5
 differential diagnosis, 41, 42
- Glanzmann's thrombasthenia (GT), 242–243
- glucose 6 phosphate dehydrogenase (G6PD) deficiency, 95–96
- graduated elastic compression stockings
 deep venous thrombosis, 133
 myeloproliferative neoplasms, 302, 304
 post-thrombotic syndrome
 prophylaxis, 135
 thromboprophylaxis, 144
- granulocyte colony-stimulating factor (G-CSF), 51
- heart block, complete, 182–183, 186
- heart disease. *See* cardiac disease
- heart valves
 defects in antiphospholipid syndrome, 180
 prosthetic. *See* prosthetic heart valves
 thrombosis, 159–160
- HELLP syndrome, 276–277, 288
 ADAMTS 13 activity, 285
 antiphospholipid syndrome, 180
 case study, 279
 differential diagnosis, 276, 277–278, 283
 thrombocytopenia, 42, 283, 288
- hematinic factors, 2
- hematocrit, 1, 2
- hematological malignancies, 320–330,
See also leukemia; lymphoma;
 myeloproliferative neoplasms
 acute, management of pregnancy, 309–316
 case studies, 330
 fertility after treatment, 320–327
 fertility preservation, 328–330
 pregnancy outcomes after treatment, 327
- hematological parameters, normal pregnancy, 1–5
- heme oxygenase inhibitors, competitive, 126
- HemoCue, 207
- hemoglobin (Hb)
 electrophoresis/HPLC, 80, 84
 gene variants, 57, 77
 structure, 77
- hemoglobin (Hb) concentrations
 after iron therapy, 22
 defining anemia, 1, 15
 normal pregnancy, 1, 2, 15
- hemoglobin A (HbA), 57
- hemoglobin Adana, 84
- hemoglobin Bart's hydrops fetalis syndrome, 67, 84
- hemoglobin C (HbC), 57
- hemoglobin E thalassemia, 89–91
- hemoglobin H disease, 67, 70
 case study, 91–92
 hydrops fetalis, 84–85
- hemoglobin S (HbS), 57
- hemoglobin SC (HbSC) disease, 58–59, 62, 64
- hemoglobin SS (HbSS) disease, 57, 58–59, 62, 77
- hemoglobin S β 0 thalassemia, 77
- hemoglobinopathies, 77–89, *See also* sickle cell disease; thalassemia
 clinical heterogeneity, 83
 global distribution, 78–80
 high affinity, 97
- molecular diagnostics, 85–87
 preimplantation genetic diagnosis, 88
 prenatal diagnosis, 83–87, 89
 screening, 80, 81, 82
 screening case studies, 89–92
 significant, 77–78
 UK NHS screening program, 80–83
- hemolysis, elevated liver enzymes and low platelets. *See* HELLP syndrome
- hemolysis/hemolytic anemia, 51–52
 autoimmune (AIHA), 40, 51–54
 causes, 52
 G6PD deficiency, 95, 96
 laboratory features, 53
 microangiopathic (MAHA), 42, 277–278
 neonatal, 54
 red cell alloimmunization, 112
 sickle cell disease, 57
 treatment, 53
 TTP, 283–284
- hemolytic disease of (fetus and newborn (HD(F)N), 112–126
 antenatal management, 118–119, 122–123
 determining risk, 117, 119–120
 future prospects, 126
 other red cell antigens, 125–126
 pathogenesis, 112–113
 postnatal management, 123–124
 prenatal diagnosis, 117–118, 119–122
 prevention, 114–116, 122–123
 RhD isoimmunization. *See* Rhesus D isoimmunization
- hemolytic uremic syndrome (HUS), 289
 case study, 290, 291
 differential diagnosis, 278, 283
 pathophysiology, 289
 thrombocytopenia, 42
 treatment, 289
- hemophilia, 246–249
 case studies, 252–253, 263
 clinical features, 246
 gene mutations, 258
 genetic counseling, 255–260
 genetic diagnosis of carriers, 258–260
 inheritance, 255, 256
 laboratory detection of carriers, 257–258
 neonatal management, 248–249
 neonatal risk, 247
 obstetric complications, 246–247
 obstetric management, 247–248
 pedigree analysis, 256–257
 prenatal diagnosis, 260–262
 somatic mosaicism, 258–260
- hemorrhage. *See* bleeding/hemorrhage
- hemosiderin, 16

Index

- hemostasis
 assessment, 11–13
 impairments in PPH, 217–219
 inherited disorders of primary, 233–243
 monitoring during PPH, 219–220
 normal pregnancy, 7–11, 284–285
 primary, 7–8
- hemostatic agents, obstetric
 hemorrhage, 211, 223–224
- heparin
 acute VTE in pregnancy, 132–133
 antiphospholipid syndrome, 182
 breastfeeding safety, 134
 inherited thrombophilia, 193
 intolerance, 145
 low molecular weight. *See* low molecular weight heparin
 management of delivery, 133–134
 monitoring in pregnancy, 133
 pre-eclampsia prevention, 273
 prosthetic heart valves, 151, 158
 rapid reversal, 170
 severe cutaneous allergy, 174
 thromboprophylaxis, 144–145
 unfractionated. *See* unfractionated heparin
- heparin-induced thrombocytopenia (HIT), 42, 144, 145
- hepatitis B vaccination, 70
- hepatitis C (HCV), thalassemia, 72
- hepcidin, 18
- hereditary elliptocytosis, 95
- hereditary pyropoikilocytosis, 95
- hereditary spherocytosis (HS), 94–95
- heritable bleeding disorders. *See* inherited bleeding disorders
- high-performance liquid chromatography (HPLC), hemoglobin, 80, 84
- hirudin, 173
- HLA associations, HPA-1a alloimmunization, 103
- HLA typing, embryos, 88
- Hodgkin's disease/lymphoma (HL)
 case study, 330
 clinical presentation, 310
 incidence, 309
 late effects on fertility, 325
 management in pregnancy, 311–312, 327, 328
- holohaptocorrin (holoHC; formerly transcobalamin III), 29–30
- holotranscobalamin (holoTC), 29–30
 serum, 33
- homocysteine, plasma total (tHcy), 33, 36, 194
- HPA (human platelet alloantigens), 103
 antibody testing, 104, 109
 genotyping, 104, 109
- HPA-1a alloimmunization, 103, 104
 clinical significance, 104
 predicting severity of FNAIT, 105
- HPA-1a/5b negative-platelets, for transfusion, 49, 106, 111
- HPA-5b alloimmunization, 103, 104
- hydrops fetalis
 hemoglobin Barts, 84
 hemoglobin H, 84–85
 postnatal management, 123–124
 red cell alloimmunization, 112, 113
- hydroxycarbamide (hydroxyurea)
 acute myeloid leukemia, 314
 myeloproliferative neoplasms, 302, 303, 304–305
 sickle cell disease, 60
- hydroxychloroquine, 184, 185, 186
- hydroxycobalamin, intramuscular, 34–35
- hydroxyurea. *See* hydroxycarbamide
- hyperbilirubinemia, neonatal
 exchange transfusion, 123–124
 phototherapy, 123
- hypertension
 chronic, 266, 270
 gestational, 266
 myelodysplastic syndrome, 314–315
- hypertensive disorders of pregnancy, 266. *See also* pre-eclampsia
 sickle cell disease, 58
 thrombocytopenia, 41–42
- hyperuricemia, 271
- hypogonadotropic hypogonadism, 68, 71
- hypotension, induced by salvaged blood, 213
- hypothalamic–pituitary axis, radiation-induced damage, 321
- hypothermia, massive transfusion, 211–212
- hypothyroidism, thalassemia, 72
- hysterectomy, 203
- idiopathic thrombocytopenic purpura (ITP), 40–49, 283
 case study, 54–55
 diagnosis, 41–44
 epidemiology, 41
 management, 44–49
 pathogenesis, 41
 prenatal counseling, 49
- imatinib, 314, 324–325, 327
- immune thrombocytopenic purpura. *See* idiopathic thrombocytopenic purpura
- in vitro fertilization (IVF),
 antiphospholipid syndrome, 185, 186
- induction of labor
 anticoagulated women, 166–167, 170
- hematological malignancies, 316
- infections. *See also* sepsis
 as cause of thrombocytopenia, 42–43
 sickle cell disease, 62
 transfusion transmitted, 241
- infertility. *See* fertility/infertility
- inherited bleeding disorders
 coagulopathies, 246–252
 disorders of primary hemostasis, 233–243
 genetic counseling and prenatal diagnosis, 255–262
 inheritance patterns, 255
- inherited red cell disorders. *See* red cell disorders, inherited
- inherited thrombophilias, 132
 case studies, 195
 diagnostic testing, 193–194
 epidemiology, 189–190
 fetal carriers, 192
 further research, 194–195
 management, 192–193
 pre-eclampsia, 271
 pregnancy loss associations, 190–191
 thromboprophylaxis, 142, 144
 very early pregnancy loss, 192
 VTE risk, 140
- instrumental delivery, ITP, 48
- interferon α (IFN- α)
 breastfeeding and, 304–305
 myeloproliferative neoplasms, 302, 303
- internal iliac arteries
 ligation, 203
 prophylactic balloon occlusion, 228
- international normalized ratio (INR), 171
- interventional radiology (IR),
 postpartum hemorrhage, 227–229
 case studies, 229–231
 outcomes, 229
 prophylactic internal iliac artery occlusion, 228
 technical aspects, 227–228
- intracranial hemorrhage (ICH), fetal/neonatal
 FNAIT, 103–104, 105
 hemophilia, 247, 248–249
 maternal ITP, 48, 49
 von Willebrand disease, 239
- intrahepatic cholestasis of pregnancy (ICP), 286–287
- intramuscular injections,
 anticoagulated women, 167, 171
- intraosseous access, obstetric hemorrhage, 207
- intrapartum management. *See* peripartum management
- intrapерitoneal transfusion (IPT),
 intrauterine, 118

- intrauterine growth restriction (IUGR),
 265
 relationship with pre-eclampsia, 269,
 270
 risk factors, 265
 sickle cell disease, 59, 61
 thalassemia, 70
 uterine artery Doppler, 271, 283
- intravascular transfusion (IVT),
 intrauterine, 118
- intravenous immunoglobulin (IVIG)
 antiphospholipid syndrome, 185
 autoimmune hemolytic anemia, 53
 complications of maternal therapy,
 108
 FNAIT, 106, 107–109
 hemolytic disease of newborn, 124
 ITP, 45–47, 49, 54
 RhD isoimmunization, 122–123
- intrinsic factor (IF), 30, 34
- iron
 absorption, 16
 bone marrow, 20–21
 cardiac, thalassemia, 71–72
 depletion, 15
 homeostasis, 16, 17
 liver, thalassemia, 72
 maternal–fetal transfer, 17–18
 requirements, 16, 17
 serum, 21
 stores, 2, 16, 20
- iron deficiency (anemia), 15–25
 case studies, 25
 causes, 18
 clinical features, 18–19
 definition, 15
 diagnosis, 20–21
 epidemiology, 15
 management, 21–23, 35
 pathophysiology, 15–18
 postpartum, 24–25
 pregnancy outcome, 19–20
 prevention, 23–24
 screening, 24
- iron dextran, 22
- iron overload
 congenital dyserythropoietic anemia,
 98
 sickle cell disease, 60
 thalassemia, 67, 68–69, 71–72
- iron supplementation, 1, 23–24
 risks, 24
 sickle cell disease, 60, 61
 thalassemia, 70
- iron therapy, 21–22
 intramuscular, 22
 oral, 21–22
 parenteral, 22
 postpartum, 25
 therapeutic trial of oral, 21
- ischemic placental disease (IPD),
 265–279
- ITP. *See* idiopathic thrombocytopenic
 purpura
- itraconazole, 315
- JAK2* gene mutations, 297, 298, 299
- Kell isoimmunization, 125, 127
- kernicterus, 112–113
- Kleihauer test, 115
- labetalol, 274
- labor analgesia
 fully anticoagulated women, 171
 hematological malignancies, 316
 hemophilia, 248
 sickle cell disease, 61
 von Willebrand disease, 239–240
 women on thromboprophylaxis, 167,
 168–169
- labor, care during. *See* peripartum
 management
- leukemia
 effects of therapy on fertility,
 324–325
 management in pregnancy, 313–314,
 327–328
 thrombocytopenia, 42
- Libman–Sacks endocarditis, 180
- liver disease
 pregnancy associated, 286–289
 thalassemia, 72
- liver function, normal pregnancy, 286
- long chain 3-hydroxyacyl-CoA
 dehydrogenase (LCHAD),
 287–288
- low birth weight
 folic acid supplements and, 36
 maternal anemia and, 19
 sickle cell disease, 59
- low-molecular-weight heparin (LMWH)
 acute VTE in pregnancy, 132–133
 antenatal maintenance therapy, 133
 antiphospholipid syndrome, 183, 184
 breastfeeding safety, 134, 160
 case studies, 136–137
 elective cesarean section, 134, 168
 inherited thrombophilia, 193, 195
 monitoring in pregnancy, 133,
 156–157
 myeloproliferative neoplasms, 302,
 304
 peripartum period, 133–134,
 166–169, 170
 postpartum continuation, 134, 167
 pre-eclampsia prevention, 273
 prosthetic heart valves, 152, 156–157,
 158
 rapid reversal, 158
- sickle cell disease, 63
 thalassemia, 70
 thromboprophylaxis, 142–143,
 144–145
- lupus anticoagulant (LAC), 178, 181
- lymphocyte count, 3–4
- lymphoma
 clinical presentation, 310
 diagnosis and staging, 310–311
 late effects on fertility, 325–326
 management in pregnancy, 311–313
 thrombocytopenia, 42
- macrocytosis, 32, 33
- magnesium sulfate, 274, 316
- malaria, 24, 78–80
- maternal mortality
 anemia, 19–20
 obstetric hemorrhage, 197, 206
 sickle cell disease, 58
 venous thromboembolism, 129, 139
- May Hegglin anomaly, 42
- mean cell hemoglobin (MCH), 2
- mean cell hemoglobin concentration
 (MCHC), 2
- mean cell volume (MCV), 1, 2
 folate deficiency, 36
- megaloblastic anemia
 folate deficiency, 36
 vitamin B₁₂ deficiency, 33, 34
- metamyelocytes, 4
- methotrexate
 hematological malignancies, 312,
 314, 324
 placenta accreta, 202
- methyl dopa, 272
- methylenetetrahydrofolate reductase
 (MTHFR) gene polymorphisms, 35
- methylmalonic acid (MMA), plasma, 33
- methylprednisolone, 45–46
- microangiopathic hemolytic anemia
 (MAHA), 42, 277–278
- microangiopathies, thrombotic (TMA),
 180, 282–290
- microcytes, hypochromic, 20
- middle cerebral artery flow, fetal,
 120–122
- miscarriage
 anti-D prophylaxis, 115
 defined, 189
 rare coagulation factor deficiencies, 252
 recurrent. *See* recurrent miscarriage
- misoprostol, 201, 210
- mitochondrial trifunctional protein
 (MTP), 287–288
- mode of delivery. *See also* cesarean
 section
 anticoagulated women, 157, 159
 hematological malignancies, 316
 ITP, 48

Index

- Modified Early Obstetric Warning Score (MEOWS), 200
- molecular diagnostics. *See* genetic testing
- monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay, 104
- monocyte count, 3, 4
- multiplex ligation-dependent probe amplification (MLPA), 86, 87, 258, 259
- myelocytes, 4
- myelodysplastic syndrome (MDS), 314–315
- myelofibrosis, primary (PMF), 293–305
 case study, 306
 diagnosis, 300
 management, 303–305
 pathogenesis, 297–299
 pregnancy outcomes, 293, 296
 treatment options, 300–303
- myeloma, 326
- myeloproliferative neoplasms (MPN), 293–305
 case studies, 305
 diagnosis, 299–300
 epidemiology, 293
 high risk pregnancy criteria, 303
 management, 301, 303–305
 pathogenesis, 297–299
 postpartum assessment, 304–305
 pregnancy outcomes, 293–297
 treatment options, 300–303
- myocardial infarction, acute
 antiphospholipid syndrome, 179
 thrombolytic therapy, 172–173
- nadroparin, 193
- NAIT. *See* fetal/neonatal alloimmune thrombocytopenia
- near patient testing. *See* point of care testing
- neonatal alloimmune neutropenia (NAIN), 51
- neonatal thrombocytopenia
 alloimmune (NAIT). *See* fetal/neonatal alloimmune thrombocytopenia
 case study, 54
 causes, 103
 maternal ITP, 41, 48, 49
- neonates
 antiphospholipid antibodies, 186
 autoimmune hemolytic anemia, 54
 Bernard-Soulier syndrome, 242
 factor XI deficiency, 251
 Glanzmann's thrombasthenia, 242
 hemoglobinopathy screening, 80–83
 hemophilia, 247, 248–249
 ITP, 48, 49
 rare coagulation factor deficiencies, 252
 von Willebrand disease, 241
- neural tube defects (NTDs), 35, 36–37
- neurological features, antiphospholipid syndrome, 180, 185
- neutropenia
 autoimmune (AIN), 40, 49–51
 chronic idiopathic (CIN), 50
 defined, 49
 differential diagnosis, 50
 grading of severity, 50
 neonatal alloimmune (NAIN), 51
- neutrophil count, 2–3
- new oral anticoagulants (NOACs), 173
 antenatal therapy, 134, 145
 prosthetic heart valves, 151
- next generation sequencing (NGS), 89
- non-transfusion dependent thalassemia (NTDT), 66–67
 complications during pregnancy, 68, 69
 obstetric care, 70, 71, 73, 74
- non-Hodgkin's lymphoma (NHL)
 clinical presentation, 310
 incidence, 309–310
 late effects on fertility, 325–326
 management in pregnancy, 312–313
- non-invasive prenatal diagnosis (NIPD), 88–89
 fetal RhD status, 120, 126
 fetal sex determination, 260–261
 hemoglobinopathies, 88–89
 hemophilia, 262
 other red cell antigens, 125–126
- non-steroidal anti-inflammatory drugs (NSAIDs), 166
- obesity, VTE risk, 140
- obstetric hemorrhage, 197–203, *See also*
 antepartum hemorrhage; postpartum hemorrhage
 anesthesia during, 210
 anesthetic management, 206–214
 antenatal assessment, 206
 blood/blood component therapy, 210–211, 220–223
 case studies, 214–215, 224
 cell salvage, 212–214
 communication, 206–207
 complications of massive, 211–212
 diagnosis, 200, 206
 estimated times to death, 197
 factor XI deficiency, 249
 fluids for resuscitation, 208–209
 hemostatic agents, 211, 223–224
 hemostatic management, 217–224
 initial resuscitation, 202, 207
 investigations, 207–208
 monitoring, 208, 209
 obstetric management, 200–203
 pharmacological control, 209–210
 post hemorrhage care, 214
 radiological management, 227–229
 thromboprophylaxis after, 214, 224
 von Willebrand disease, 237
- ofatumumab, 326
- oocyte cryopreservation, 329
- operative delivery. *See* cesarean section
- opioid analgesia
 labor in anticoagulated women, 171
 painful sickle crises, 62
- oral anticoagulants. *See* new oral anticoagulants; vitamin K antagonists
- oral contraceptive pill, sickle cell disease, 59–60
- osteoporosis, thalassemia, 72
- ovarian failure
 acute leukemias, 324
 chemotherapy-induced, 320–321, 322, 323
 lymphomas, 325–326
 radiation-induced, 320–321, 322
 single-agent chemotherapy, 322–324
- ovarian tissue, cryopreservation, 329
- oxytocin (Syntocinon), 201, 209, 316
- packed cell volume (PCV)
 defining erythrocytosis, 299
 myeloproliferative neoplasms, 300, 302–303
- pagophagia, 18–19
- pain management
 acute sickle crises, 62
 during labor. *See* labor analgesia
- parietal cell antibodies, 34
- parvovirus B19, 99, 241
- pedigree analysis, hemophilia, 256–257
- pelvic irradiation. *See* abdomino-pelvic irradiation
- penicillin, 60
- Perinatal Antiplatelet Review of International Studies (PARIS), 272–273
- peripartum management
 anticoagulants, 165–174
 factor XI deficiency, 250
 full anticoagulation, 133–134, 169–172
 hematological malignancies, 316
 hemophilia, 247–248
 iron deficiency anemia, 23
 ITP, 47–49
 myeloproliferative neoplasms, 304
 pre-eclampsia, 273–274
 prosthetic heart valves, 157–159
 sickle cell disease, 63
 thalassemia, 74
 thromboprophylaxis, 165–169
 von Willebrand disease, 239–240

- pernicious anemia, 34, 37
 Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL), 314
 phototherapy, 123
 phytonadione, 96
 pituitary dysfunction, thalassemia, 68
 placenta
 manual removal, 202
 retained, 217, 218
 placenta accreta, 199, 202, 227
 placenta previa
 anteartum hemorrhage, 197
 postpartum hemorrhage, 199, 217, 227
 placental abruption, 265–266
 anteartum hemorrhage, 197
 case studies, 12–13, 224
 hemostatic changes, 211, 217, 218
 management, 277
 placental disease
 antiphospholipid syndrome, 179
 high risk pregnancies, 283
 ischemic (IPD), 265–279
 pre-eclampsia, 267–269
 pregnancy loss, 190
 placental infarction, myeloproliferative neoplasms, 297–299
 placental protein 13 (PP-13), 283
 placentation
 abnormal, 199, 217, 218, 227
 normal, 190
 plasma exchange (PEX)
 antiphospholipid syndrome, 185
 hemolytic uremic syndrome, 289, 290, 291
 RhD isoimmunization, 122
 TTP, 285–286
 plasma volume, 1, 15
 plasmapheresis. *See* plasma exchange
 plasmin, 9
 plasminogen activator inhibitor (PAI), 9
 platelet counts, 41, *See also* thrombocytopenia
 case study, 5
 fetal, 48
 heparinized pregnant women, 133
 ITP intervention thresholds, 44, 45
 myeloproliferative neoplasms, 300, 302, 303
 neonatal, 49
 normal pregnancy, 4, 7–8
 platelet function analysis (PFA), 4–5
 anticoagulated parturients, 173
 von Willebrand disease, 237
 platelet transfusion
 Glanzmann's thrombasthenia, 242
 HELLP syndrome, 277
 intrauterine, FNAIT, 106–107, 108
 ITP, 45–47
 neonates with FNAIT, 105–106, 111
 obstetric hemorrhage, 211, 217, 223
 platelets, 4–5
 inherited disorders of function, 241, 242–243
 ITP-related changes, 44
 primary hemostasis, 7
 size/volume, 4
 Plummer–Vinson syndrome, 19
 point of care testing (POCT), 11–13
 anticoagulated women, 173–174
 obstetric hemorrhage, 207–208, 220, 224
 polycythemia vera (PV), 293–305
 case study, 305–306
 diagnosis, 299–300
 management, 303–305
 pathogenesis, 297–299
 pregnancy outcomes, 293, 295
 treatment options, 300–303
 posaconazole, 315
 post-dural puncture headache, anticoagulated women, 172
 postpartum hemorrhage (PPH), 197, *See also* obstetric hemorrhage
 anesthetic management, 206–214
 blood/blood product transfusion, 220–223
 case studies, 224, 229–231
 diagnosis, 200
 drug management, 201–202, 209–210
 factor XI deficiency, 250–251
 fibrinogen as biomarker, 218–219, 220
 hematological malignancies, 316
 hemostatic agents, 211, 223–224
 hemostatic impairment, 217–219
 hemostatic management, 220–224
 immediate management, 200–202
 ITP, 47
 monitoring hemostasis, 219–220
 obstetric management, 202–203
 pathogenesis, 199
 prevention, 197–199
 prosthetic heart valves, 157
 radiological management, 227–229
 risk factors, 198, 227, 228
 sickle cell disease, 59
 thromboprophylaxis after, 214, 224
 volume maintenance, 202
 von Willebrand disease, 237, 240
 post-thrombotic syndrome (PTS), 134–135
 PPH. *See* postpartum hemorrhage
 pravastatin, 273
 prednisolone
 antiphospholipid syndrome, 184
 FNAIT, 107, 108
 ITP, 45–46, 54
 pre-eclampsia (PET), 265, 266–279
 antiphospholipid syndrome, 180, 271
 case studies, 278–279
 complications, 267
 diagnosis, 267
 differential diagnosis, 277–278, 283
 epidemiology, 266–267
 hematological complications, 275–278
 liver involvement, 288–289
 long-term consequences, 269–270
 management guidelines, 274
 pathogenesis, 267–269, 270
 pharmacological therapy, 274
 prediction, 271, 283
 prevention, 271–273
 relationship with IUGR, 269, 270
 risk factors, 266
 sickle cell disease, 58, 61
 thrombocytopenia, 41–42, 275, 283
 thrombophilia and, 271
 timing of delivery, 273–274
 uterine artery Doppler, 271, 283
 pregnancy
 normal cellular changes, 1–5
 normal coagulation changes, 7–13
 pregnancy loss, 189, *See also* miscarriage; stillbirths
 antiphospholipid syndrome, 180
 case studies, 195, 290
 dilemmas, 194
 epidemiology, 189
 fetal thrombophilia, 192
 further research, 194–195
 inherited thrombophilia association, 190–191
 intrahepatic cholestasis of pregnancy, 287
 management, 192–193
 pathogenesis, 190–192
 placental pathology, 190
 terminology, 189
 thrombophilia testing, 194
 pregnancy-associated placental protein A (PAPP-A), 283
 preimplantation genetic diagnosis (PGD)
 hemoglobinopathies, 88
 hemophilia, 262
 thalassemia, 69, 88
 prenatal diagnosis
 hemoglobinopathies, 83–87
 hemophilia, 260–262
 heritable bleeding disorders, 255
 non-invasive. *See* non-invasive prenatal diagnosis
 rare bleeding disorders, 262
 red cell alloimmunization, 117–118, 119–122
 von Willebrand disease, 238

Index

- pre-pregnancy counseling
 antiphospholipid syndrome, 182–183
 hemophilia, 247
 ITP, 49
 myeloproliferative neoplasms, 303
- preterm delivery
 antiphospholipid syndrome, 180
 hematological malignancies, 313, 316
 maternal anemia and, 19
 pre-eclampsia, 273–274
 sickle cell disease, 59
- preterm premature rupture of membranes (PPROM), 315
- primary thrombocythemia. *See* essential thrombocythemia
- prosthetic heart valves, 150–160
 antenatal anticoagulation, 145, 151–157, 159
 biological vs mechanical, 150
 case studies, 160–161
 indications, 150
 need for thromboprophylaxis, 151
 peripartum management, 157–159
 valve thrombosis, 159–160
- protamine, 158, 170
- protein C, 9–11
 activated. *See* activated protein C
 testing in pregnancy, 132, 194
- protein C deficiency, 189–190
 pregnancy loss, 191
 VTE risk, 132, 144
- protein S, 9–11
 case study, 12
 testing in pregnancy, 132, 194
- protein S deficiency, 189–190
 pregnancy loss, 191
 VTE risk, 132, 144
- protein/creatinine (P/C) ratio, urinary, 266
- prothrombin (factor II) deficiency, 251–252
- prothrombin antibodies, 182
- prothrombin complex concentrates (PCC), 158–159
 factor II or X deficiencies, 251
 obstetric hemorrhage, 223–224
- prothrombin G20210A mutation, 190
 case studies, 195
 pregnancy loss, 191
 VTE risk, 132, 144
- prothrombin time (PT), 11
 obstetric hemorrhage, 217, 223
 pre-eclampsia, 275
- pseudothrombocytopenia, 42, 43, 44
- puerperium, normal cellular changes, 1–5
- pulmonary embolism (PE), 129, *See also* venous thromboembolism
 case study, 174
- diagnosis in pregnancy, 130–132
 diagnostic radiation exposure, 131
 massive life-threatening, 135–136, 172–173
- pyropoikilocytosis, hereditary, 95
- pyrosequencing, 85–86
- pyruvate kinase deficiency, 96–97, 100
- racial differences. *See* ethnic differences
- radiation exposure, 131
- radiology, interventional. *See* interventional radiology
- radiotherapy
 effects during pregnancy, 327–328
 fertility preservation, 328–330
 Hodgkin's disease, 312
 infertility after, 321–322
 pregnancy outcomes after, 327
- recurrent miscarriage
 antiphospholipid syndrome, 180
 case studies, 195
 defined, 189
 further research, 194–195
 inherited thrombophilia, 191
 management, 192–193
 pathogenesis, 191
 thrombophilia testing, 194
- red cell alloimmunization, 112–126
 case studies, 127
 cell salvage, 213–214
 other red cell antigens, 125–126
 pathogenesis, 112–113
 RhD. *See* Rhesus D isoimmunization
 sensitizing events, 112, 115
 sickle cell disease, 62
 thalassemia, 68, 72
- red cell antibodies
 maternal testing, 119–120
 pathophysiology, 112–113
- red cell count, 1, 2
- red cell disorders, inherited, 93–99, *See also* hemoglobinopathies
 case studies, 100
 congenital dyserythropoietic anemia, 97–98
 enzymopathies, 95–97
 membrane disorders, 94–95
- red cell indices
 iron deficiency anemia, 20
 normal pregnancy, 1, 2
- red cell mass, 1, 15
- red cells
 development, 93–94
 normal pregnancy, 1–2
- regional anesthesia. *See also* central neuraxial blockade; epidural analgesia
 factor XI deficiency, 250
 fully anticoagulated women, 134, 172
 hemophilia, 248
- obstetric hemorrhage, 210
 sickle cell disease, 61
 women on thromboprophylaxis, 145, 167–169
- remifentanyl, 171
- renal disease
 antiphospholipid syndrome, 180
 hemolytic uremic syndrome, 289
- restless legs syndrome, 19
- reticulocytes, 93, 94
 hemoglobin content, 20
- RHCE gene, 113–114
- RHD gene, 113–114
 DNA testing, 116–117
 variants, 114, 124–125
- RHD pseudogene, 124
- RHD/CE hybrids, 124–125
- Rhesus c isoimmunization, 125–126
- Rhesus D blood group
 determination, 116–117, 119–120
 genotypes and phenotypes, 113–114
- Rhesus D isoimmunization, 113–125
 case study, 127
 cell salvage, 214
 current management, 119–123
 future prospects, 126
 hemolytic disease. *See* hemolytic disease of newborn
 pediatric management, 123–124
 postnatal management, 123–124
 prevention, 114–116
 sensitizing events, 112, 115
 thalassemia, 68, 72
 traditional management, 116–119
- Rhesus E isoimmunization, 125–126
- rheumatic heart disease, 150, 160
- ristocetin cofactor assay (VWF RCo), 236
- ristocetin induced platelet agglutination (RIPA), 236
- rituximab
 autoimmune hemolytic anemia, 53
 ITP, 47
 lymphoma, 312, 325–326
- rivaroxaban, 134, 145, 151, 173
- romiplostim, ITP, 47
- rotational elastometry (ROTEM®), 11–13
 anticoagulated women, 173–174
 obstetric hemorrhage, 220, 221
- Sanger sequencing, 85, 86
- Schwachman–Diamond syndrome, 99
- sepsis
 chemotherapy associated, 315
 maternal neutropenia, 51
- short tandem repeats (STRs), 87, 88
- sickle cell anemia, 57, 58–59
 antenatal blood transfusion, 62
 case study, 63–64

- sickle cell disease (SCD), 57–63
 antenatal care, 61–63
 case studies, 63–64
 clinical features, 57–58
 delivery, 63
 detection methods, 80, 85
 epidemiology, 57
 fertility and contraception, 59–60
 fetal complications and outcomes, 59
 geographical distribution, 80
 maternal complications, 58–59
 molecular basis, 84
 molecular diagnostics, 86
 postnatal management, 63
 preconception care, 60
 pregnancy and, 58
 preimplantation genetic diagnosis, 88
 prenatal diagnosis, 78, 83–87, 89
 screening, 80
 UK NHS screening program, 80–83
- sickle crises, painful, 57, 58, 61, 62
- sickle solubility test, 80
- somatic mosaicism, hemophilia
 carriers, 258–260
- spherocytosis, hereditary (HS), 94–95
- spinal blocks
 fully anticoagulated women, 172
 ITP, 48
 von Willebrand disease, 239–240
 women on thromboprophylaxis, 167–168, 169
- splenectomy, 99
 ITP, 47
 pyruvate kinase deficiency, 100
 thalassemia, 67, 70
- statins, 273
- stem cell transplantation (SCT)
 fertility after, 322–324
 pregnancy outcomes after, 327
- stillbirths
 RhD isoimmunization, 117
 sickle cell disease, 59
- streptokinase, 136
- subacute combined degeneration of the cord, 31
- sulproston, 202
- Swiss-cheese heterochromatin, 98
- Syntocinon. *See* oxytocin
- systemic lupus erythematosus (SLE)
 acute exacerbation, 289–290
 antiphospholipid syndrome, 177, 178
 differential diagnosis, 283
 management in pregnancy, 185
 pre-pregnancy management, 182–183
- T cell lymphoma, 309, 312–313
- thalassemia, 66–74
 α . *See* α thalassemias
 β . *See* β thalassemias
- blood transfusion, 67–68, 70
 carriers, 69–70
 case studies, 74–75, 89–92
 classification, 66–67
 detection methods, 80, 85
 global distribution, 66, 78–80
 iron overload, 67, 68–69, 71–72
 labor and delivery, 74
 molecular basis, 77
 molecular diagnostics, 85–87
 non-transfusion dependent. *See* non-transfusion dependent thalassemia
 postpartum care, 74
 preconception and antenatal care, 69–73
 preimplantation genetic diagnosis, 69, 88
 prenatal diagnosis, 78, 79, 83–87, 89
 screening, 69, 80–89
 UK NHS screening program, 80–83
- thalassemia intermedia. *See* non-transfusion dependent thalassemia
- thalassemia major (TM), 67
 case studies, 74–75
 complications during pregnancy, 67–69
 obstetric care, 69, 70–74
 rationale for screening, 80
- thalassemia minor, 69–70
- thalassemia trait, 67, 69–70
- third stage of labor, active management, 199, 316
- thrombin activatable inhibitor of fibrinolysis (TAFI), 9
- thrombin, generation, 8
- thrombocytopenia, primary/essential.
See essential thrombocytopenia
- thrombocytopenia
 antiphospholipid syndrome, 180, 185
 case studies, 54–55
 causes in pregnancy, 41–43
 fetal/neonatal alloimmune. *See* fetal/neonatal alloimmune
 thrombocytopenia
 gestational. *See* gestational thrombocytopenia
 HELLP syndrome, 42, 283, 288
 hereditary (constitutional), 42
 idiopathic/immune. *See* idiopathic thrombocytopenic purpura
 moderate to severe, in pregnancy, 282–283
 neonatal. *See* neonatal thrombocytopenia
 obstetric hemorrhage, 211, 217, 218
 pre-eclampsia, 41–42, 275, 283
 spurious (pseudo-), 42, 43, 44
- thrombocytosis, 299
- thromboelastography (TEG), 11–13
 anticoagulated women, 173–174
- obstetric hemorrhage, 208
- thromboembolic disease. *See* venous thromboembolism
- thrombolytic therapy, 136, 172–173
- thrombomodulin, 10
- thrombophilia. *See also* antiphospholipid syndrome
 epidemiology, 189–190
 heritable. *See* inherited thrombophilias
 pre-eclampsia risk, 271
 testing, 132, 193–194
 thromboprophylaxis, 142, 144
 VTE risk, 140
- thrombopoietin agonists, ITP, 47
- thromboprophylaxis, 139–146
 after obstetric hemorrhage, 214, 224
 autoimmune hemolytic anemia, 53
 case study, 174–175
 efficacy and safety in pregnancy, 139
 management strategies, 140–143
 myeloproliferative neoplasms, 300–302, 303–304
 non-pharmacological, 144
 peripartum period, 165–169
 pharmacological, 144–146
 risk factor assessment, 140, 141, 142, 143
 sickle cell disease, 62–63
 von Willebrand disease, 240
- thrombosis
 antiphospholipid syndrome, 179
 management in pregnancy, 183
 myeloproliferative neoplasms, 297–299
 previous, antiphospholipid syndrome, 183
 rare coagulation factor deficiencies, 252
 TTP, 284
 venous. *See* venous thromboembolism
- thrombotic endocarditis, non-bacterial, 180
- thrombotic microangiopathies (TMA), 180, 282–290
- thrombotic thrombocytopenic purpura (TTP), 283–286
 acquired, 285, 286
 case study, 290, 291
 congenital, 285, 286
 differential diagnosis, 277, 282, 283
 pathophysiology, 284
 presentation in pregnancy, 285
 previous acquired idiopathic, 285
 subsequent pregnancies, 286
 thrombocytopenia, 42
 treatment of acute, 285–286
- thyroid function, thalassemia, 72
- ticlopidine, 166

Index

- tin-mesoporphyrin, 126
 tinzaparin, 133, 145
 tissue factor, 11
 tissue factor pathway inhibitor (TFPI), 11
 tissue plasminogen activator (tPA), 9
 total body irradiation (TBI), 322
 total iron binding capacity (TIBC), 21
 tranexamic acid, 9
 hemophilia, 248
 inherited disorders of platelet function, 242
 ITP, 47
 obstetric hemorrhage, 202, 211, 223
 rare coagulation factor deficiencies, 251
 von Willebrand disease, 239, 240
 transarterial embolization (TAE),
 postpartum hemorrhage, 227–229
 transcobalamin, 29–30
 transferrin (Tf), 16, 17–18
 saturation, 21
 transferrin receptors (TfR), 17–18
 soluble (sTfR), 21
 transfusion dependent anemias, 94
 transfusion related acute lung injury (TRALI), 212, 222
 transfusion transmitted infections,
 VWF concentrates, 241
 TTP. *See* thrombotic thrombocytopenic purpura
 tyrosine kinase inhibitors, 324–325,
 327, *See also* imatinib
- ultrasound
 antiphospholipid syndrome, 184
 deep venous thrombosis, 130
 fetal middle cerebral artery, 120–122
 fetal sex determination, 260
 guiding femoral artery access, 228
 hydrops fetalis, 113
 sickle cell disease, 61
 thalassemia, 70
 umbilical cord, delayed clamping, 23
 unfractionated heparin (UFH)
 acute VTE in pregnancy, 132–133
 massive pulmonary embolism, 136
 monitoring in pregnancy, 133
 peripartum period, 134, 166–167,
 169, 170
 prosthetic heart valves, 152, 156, 158
 rapid reversal, 170
 thromboprophylaxis, 144, 145
 urinary tract infections, sickle cell disease, 58
 ursodeoxycholic acid (UDCA), 287
 uterine artery Doppler
 antiphospholipid syndrome, 184
 myeloproliferative neoplasms, 304
 pre-eclampsia and IUGR, 271, 283
 uterine artery embolization (UAE), 203,
 227–229
 case study, 231
 outcomes, 229
 technical aspects, 227–228
 uterine atony, 197, 199, 227
 hemostatic changes, 217, 218
 management, 201–202, 209–210
 uterotonic agents, 201, 202, 209–210
 uterus
 balloon tamponade, 202
 bimanual compression, 202
 massage, 201
 packing with surgical gauze, 202–203
 radiation-induced damage, 321–322
 rupture, 217
- vaccinations
 sickle cell disease, 60
 splenectomized patients, 99
 vardenafil, 273
 vascular endothelial growth factor (VEGF), 268
 vaso-occlusive crises, sickle cell disease,
 57, 58
 vasopressin, 202
 venesection, therapeutic, 302–303
 venous thromboembolism (VTE),
 129–136
 antiphospholipid syndrome, 179
 assessment and diagnosis of acute,
 130–132
 case studies, 136–137
 initial treatment in pregnancy,
 132–133
 maintenance antenatal treatment,
 133
 maternal mortality, 129, 139
 pathogenesis, 129–130, 139–140
 peripartum management, 133–134
 postpartum anticoagulation, 134
 post-thrombotic syndrome, 134–135
 previous, 140, 142, 144, 183
 prophylaxis. *See* thromboprophylaxis
 risk factor assessment, 140, 141, 142,
 143
 sickle cell disease, 62–63
 symptoms and signs, 129, 130
 thalassemia, 70
 thrombophilia testing, 132
 ventilation perfusion (V/Q) scanning,
 131
 vertebral canal hematoma,
 165, 167
 vinblastine, 311
 viral infections, thrombocytopenia,
 42–43
 Virchow's triad, 129, 140
- viscoelastomeric hemostatic assays (VHA), 220
 vitamin B₁₂, 29–30
 serum, 2, 32–33
 therapy, 34–35
 vitamin B₁₂ deficiency
 case study, 37
 causes, 30, 31
 clinical features, 30–31, 32
 diagnosis, 31–34
 management, 34–35
 pregnancy outcomes, 31
 vitamin D supplements, thalassemia, 72
 vitamin K
 newborn infants, 96, 241, 248
 rare coagulation factor deficiencies,
 251
 reversal of anticoagulation, 158
 vitamin K antagonists (VKA), 152–155,
 See also warfarin
 adverse fetal effects, 152–154, 155
 dose and fetal complications,
 154–155
 peripartum management, 158
 prosthetic heart valves, 150, 151,
 152–155
 reversal, 158–159, 171
 von Willebrand disease (VWD), 7,
 233–241
 antenatal management, 237–239
 case studies, 243–244
 classification, 234–235
 clinical features, 234
 diagnostic algorithm, 236
 inheritance, 255
 intrapartum management, 239–240
 laboratory evaluation, 235–237
 neonatal management, 241
 obstetric complications, 237
 postpartum management, 240
 pre-pregnancy management, 237,
 238
 thrombocytopenia, 42
 von Willebrand factor (VWF), 7,
 233–234
 concentrates, 238–239, 240, 241
 factors affecting plasma levels, 234
 laboratory tests, 236
 multimers, 233, 236–237
 normal pregnancy, 7, 237, 284–285
 TTP, 284
 VTE. *See* venous thromboembolism
 VWF. *See* von Willebrand factor
- warfarin
 adverse fetal effects, 145, 152–154,
 155
 antenatal thromboprophylaxis, 143,
 145–146

- antiphospholipid syndrome, 185
- dose and fetal complications, 154–155
- peripartum period, 170, 171
- postpartum period, 134, 143, 145, 160
- prosthetic heart valves, 145, 152, 153
- reversal, 158–159, 171
- warfarin embryopathy, 145, 152–154, 155
 - effects of dose, 155
- warfarin fetopathy, 154
 - dose dependence, 154–155
- warm antibody autoimmune hemolytic anemia, 52
- Well's score, 131–132
- white cell counts (WCC)
 - case study, 5
 - differential, 2–4
 - total, 2, 3
- white cells, 2–4
- zinc protoporphyrin (ZPP), 21